<DOC>
	<DOCNO>NCT00157508</DOCNO>
	<brief_summary>Aspirin commonly use treatment painful inflammatory disease prevention cardiovascular disease . A major drawback aspirin treatment well recognize gastrointestinal toxicity . Recent research indicate couple nitric oxide ( NO ) derivate aspirin moiety retain therapeutic effect avoid undesirable gastrointestinal side effect . NO cytoprotective effect , blood flow modulation , mucus release repair mucosal injury . NCX4016 , NO-releasing derivative acetylsalicilic acid , show retain analgesic , anti-inflammatory antithrombotic activity aspirin , less gastrointestinal toxicity . In addition , preliminary data suggest NCX4016 may restore insulin sensitivity eNOS deficient mouse . This study aim evaluate activity NCX4016 , compare aspirin , albuminuria , insulin sensitivity cardiac renal hemodynamic patient type 2 diabetes mellitus . The patient one month placebo treatment , enter two 1-month treatment period , equivalent dos ( 800 mg NCX4016 , 325 mg aspirin ) NCX4016 aspirin .</brief_summary>
	<brief_title>Renal Systemic Effects NCX4016 Patients With Type 2 Diabetes Early Nephropathy</brief_title>
	<detailed_description>Nitric oxide-releasing , non-steroidal anti-inflammatory drug ( NO-NSAIDs ) new chemical entity obtain add nitric oxide-releasing moiety parent NSAID via short-chain ester linkage . NCX4016 ( Nitro-aspirin ) , acetoxy-benzoate 2- ( 2-nitroxymethyl ) -phenyl ester acetylsalicylic acid , one novel compound developed dual aim expand pharmacological property parent drug spare side effect , particular gastrointestinal mucosa . Decreased NO synthesis may contribute abnormality associate diabetes decrease insulin activity , impair endothelium-dependent/insulin-induced vasodilatation , increase sympathetic vasoconstrictor outflow increase platelet activation , may result increase vascular resistance arterial hypertension , long term , increase risk micro- macrovascular complication . Low-dose aspirin represent antiplatelet drug choice prevention vascular complication diabetes . Preclinical data NCX4016 support possibility Nitro-aspirin may shear aspirin antithrombotic activity may offer additional benefit relate increase NO bioavailability . Actually NCX4016 inhibits cyclooxygenase ( COX ) activity platelet vitro ex vivo , similar aspirin , prevents release thromboxane ( TX ) A2 arachidonic acid-induced platelet aggregation . Moreover Nitro-aspirin inhibits aspirin-insensitive platelet aggregation adhesion , possibly inhibit expression platelet adhesion molecule specific COX-independent mechanism , probably NO-mediated , show parent compound . Therefore Nitro-aspirin exceed cardioprotective action parent compound , add aspirin-like moiety NO-releasing moiety , contribute benefit effect , multiple anti-thrombotic , possibly , anti-atherosclerotic activity , restoration insulin-related metabolic vascular effect finally blood pressure reduction . Moreover , experimental clinical data suggest Nitro-aspirin offer significant safety advantage NO moiety may limit aspirin gastrotoxicity prevent vasocontriction mucosal microvasculature . In present randomise , double-blind , cross-over study , evaluate efficacy safety profile Nitro-aspirin ( 800 mg bid ) , equiactive dose aspirin ( 325 mg od ) , compare placebo , thirteen patient type 2 diabetes micro macro-albuminuria ( overnight albumin excretion rate &gt; 20 Âµg/min least 6 month ) , without overt renal insufficiency ( serum creatinine concentration &lt; 2 mg/dl ) specific controindication aspirin therapy . Eligible patient provide write informed consent , withdraw previous treatment NSAIDs aspirin , 4-week placebo run-in period , enter two consecutive 4-week treatment period Nitro-aspirin plus aspirin placebo Nitro-aspirin placebo plus aspirin random order . Primary efficacy variable change urinary albumin excretion ( UAE ) insulin activity end Nitro-aspirin treatment compare baseline . UAE ( mean three overnight urine collection ) , insulin sensitivity ( glucose disposal rate measure hyperinsulinemic euglycemic clamp ) , cardiac haemodynamics ( evaluate echocardiography ) , NO bioavailability oxidative stress ( measure nitrite/nitrate plasma level ) clinical laboratory variable , measure baseline end treatment period .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Nitroaspirin</mesh_term>
	<criteria>Male female patient affect type 2 diabetes stable metabolic control ( HbA1c &lt; 9 % ) , stable systemic blood pressure control ( SBP/ DBP &lt; 160/90 mmHg ) . Presence early nephropathy ( overnight albumin excretion rate &gt; 20 microg/ min least 6 month ) , without overt renal insufficiency ( serum creatinine concentration &lt; 2 mg/dl ) . Age 18 75 year . Written sign informed consent ; patient willing able comply study procedure schedule visit . History form allergic reaction hypersensitivity intolerance contraindication acetylsalicylic acid nitrate . Patients age 18 75 . Patients able give inform consent inadequate comprehension study risk requirement . Patients unable comply requirement study protocol . Chronic alcohol drug abuse ( current within past year ) . Pregnancy lactation . If woman childbearing potential , pregnancy test must perform inclusion study , reliable contraceptive method follow . Evidence nondiabetic renal disease . Patients duodenal/gastric ulcer history , gastrointestinal bleeding last 6 month . Patients liver insufficiency ( ASAT , ALAT &gt; 2 time upper normal limit ) . Patients platelet count &lt; 100,000 cells/mm3 . Patients hemorrhagic diathesis . Patients antiinflammatory immunosuppressive therapy last 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2005</verification_date>
</DOC>